(0.04%) 5 475.65 points
(0.07%) 38 804 points
(-0.05%) 17 848 points
(0.27%) $80.55
(0.75%) $2.81
(0.14%) $2 332.30
(-0.22%) $29.33
(-0.05%) $970.40
(0.00%) $0.932
(-0.17%) $10.64
(0.05%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications...
Stats | |
---|---|
Šios dienos apimtis | 120 551 |
Vidutinė apimtis | 132 241 |
Rinkos kapitalizacija | 884.94M |
EPS | $-0.0427 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.320 ) 2024-08-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-16.10 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0880 (0.46%) |
Tūris Koreliacija
Silence Therapeutics plc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ICHR | 0.893 |
TNYA | 0.879 |
SRTS | 0.879 |
REYN | 0.866 |
PYXS | 0.86 |
LRMR | 0.858 |
VERA | 0.857 |
AVIR | 0.855 |
KYMR | 0.85 |
YMAB | 0.847 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
VALN | -0.876 |
CNTY | -0.854 |
BSGM | -0.843 |
VNET | -0.839 |
WABC | -0.837 |
BFRI | -0.833 |
GSBC | -0.825 |
GSM | -0.824 |
VRM | -0.824 |
DSWL | -0.823 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Silence Therapeutics plc Koreliacija - Valiuta/Žaliavos
Silence Therapeutics plc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $25.38M |
Bruto pelnas: | $15.06M (59.34 %) |
EPS: | $-1.170 |
FY | 2023 |
Pajamos: | $25.38M |
Bruto pelnas: | $15.06M (59.34 %) |
EPS: | $-1.170 |
FY | 2022 |
Pajamos: | $17.50M |
Bruto pelnas: | $6.62M (37.83 %) |
EPS: | $-1.260 |
FY | 2021 |
Pajamos: | $12.42M |
Bruto pelnas: | $4.96M (39.94 %) |
EPS: | $-1.329 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.